Caris Life Sciences, Inc. (CAI) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-05-12

Key Insights

Director Jeff L Vacirca purchased 31,050 shares of CAI on 05/11/2026 at a weighted average price of $16.149, with individual transaction prices ranging from $16.13 to $16.15, indicating deliberate accumulation at relatively consistent pricing.
Following this transaction, Vacirca's total beneficial ownership increased to 49,671 shares held directly, suggesting meaningful personal investment commitment in the company by a board member.
The timing and size of this insider purchase (approximately $501,000 notional value) during a concentrated price range may signal confidence in CAI's near-term prospects or valuation levels by someone with access to material non-public information.

Want the newest filings?

This analysis covers the filing from 2026-05-12. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-03-10

David D. Halbert, the founder, chairman, and CEO of Caris Life Sciences, has acquired a substantial direct and indirect ownership stake in the company, holding over 123.6 million shares or around 10% of the total outstanding shares.
Halbert's ownership is spread across multiple entities, including Caris Halbert, L.P., ADAPT I Ltd., Carisome I, L.P., Caris Investment II Ltd, Caris Investment III Ltd, and Halbert Family Capital, LLC, indicating a complex ownership structure.
The award of 320,112 restricted stock units to Halbert further increases his alignment with shareholders, as the vesting of these units will be dependent on the company's performance.

Filed: 2026-03-10

Brian J. Brille, the Vice Chairman and Executive Vice President of Caris Life Sciences, Inc. (CAI), acquired 83,162 shares of the company's common stock through a restricted stock unit award.
Brille also holds an indirect beneficial ownership of 500,000 shares of CAI common stock through a family trust, indicating his significant stake in the company.
The Form 4 filing suggests that Brille continues to have a strong commitment to and confidence in the company's long-term growth and performance.

Filed: 2026-03-10

The reporting person, David Baxley Spetzler, who is the President of Caris Life Sciences, Inc. (CAI), acquired 83,162 shares of common stock through a restricted stock unit award.
The acquisition of 83,162 shares increases Spetzler's direct beneficial ownership of CAI common stock to 543,939 shares, indicating a significant insider investment in the company.
The timing of the transaction, in March 2026, suggests Spetzler's confidence in the company's future performance and aligns his interests with those of other shareholders.

Filed: 2026-03-10

The reporting person, John Russel Denton, acquired 63,971 shares of Caris Life Sciences, Inc. common stock through a restricted stock unit award, indicating potential confidence in the company's future.
Denton also holds an indirect beneficial ownership of 9,184 shares of common stock through a trust, further demonstrating his investment in the company.
The transaction was made on March 6, 2026, suggesting recent insider activity and ongoing commitment to the company.

Filed: 2026-03-10

The reporting person, Luke Thomas Power, acquired 63,971 shares of Caris Life Sciences, Inc. (CAI) common stock through a restricted stock unit award, increasing his direct beneficial ownership to 163,542 shares.
This transaction reflects the company's executive compensation program, as Power holds the role of Senior Vice President, Chief Financial Officer, and Chief Accounting Officer.
The filing does not indicate any sales or disposals of Caris Life Sciences shares by the reporting person, suggesting potential confidence in the company's long-term prospects.

Filed: 2026-03-02

Insider Lloyd Minor, a director of Caris Life Sciences, acquired 2,492 shares of the company's common stock at a price of $20.06 per share, increasing his direct ownership to 18,621 shares.
The shares were acquired in lieu of cash compensation for Minor's 2025 board retainer fees, indicating a willingness to receive equity as part of his director compensation.
This transaction suggests Minor's confidence in the company's long-term prospects and aligns his interests with those of other shareholders.

Filed: 2026-01-13

Insider Peter M. Castleman acquired 2,500 additional shares of Caris Life Sciences, Inc. (CAI) through the exercise of stock options, indicating his continued confidence in the company.
Castleman also holds a significant indirect beneficial ownership of 10,270,906 shares through CLS-PF-SPE, LLC, suggesting he has a substantial stake in the company.
The stock option exercise and Castleman's large indirect ownership position suggest he believes in the long-term growth potential of Caris Life Sciences.

Other reports for Caris Life Sciences, Inc.

Quarterly Report Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.